Severe Asthma ToolkitSevere Asthma Toolkit
HomeAboutSpecific PopulationsRegistriesContributorsContact
Twitter
  • What is Severe Asthma?
    • Overview
    • Definition
    • Prevalence & Burden
    • Pathophysiology
    • Symptoms
    • Severe Asthma Attacks / Exacerbations / Flare-ups
    • Asthma Phenotypes
  • Diagnosis & Assessment
    • Overview
    • Diagnosis Overview
    • Assessment Overview
    • Lung Function Assessments
    • Questionnaires
    • Allergy Assessments
    • Phenotyping
    • Bronchoscopy
    • Imaging
    • Occupational Asthma
  • Management
    • Overview
    • Asthma Education
      • About Severe Asthma
      • Asthma Pathophysiology
      • Medications Education
      • Self-Monitoring
      • Triggers
      • Review
    • Written Action Plans
    • Adherence
    • Inhaler Technique
    • Physical Activity & Exercise
    • Interdisciplinary Approach & Multidimensional Assessment
    • Referral
  • Medications
    • Overview
    • Relievers
    • Preventers / Controllers
    • Add-on Therapies
    • Monoclonal Antibodies
    • Bronchial Thermoplasty
  • Co-Morbidities
    • Overview
    • Pulmonary & Upper Airways
      • Allergic & Non-Allergic Rhinitis
      • Chronic Rhinosinusitis
      • Dysfunctional Breathing
      • Vocal Cord Dysfunction
      • Chronic Obstructive Pulmonary Disease
      • Bronchiectasis
      • Obstructive Sleep Apnoea
    • Extra-Pulmonary
      • Obesity
      • Anxiety & Depression
      • Gastro-oesophageal Reflux Disease (GORD)
      • Osteoporosis
      • Cardiovascular Disease & Metabolic Disease
  • Living with Severe Asthma
    • Overview
    • Daily Symptom Burden
    • Mental & Emotional Health
    • Intimacy & Relationships
    • Self-Management Support
    • Medication Use & Costs
    • Experience of Care
    • Experience of Asthma Attacks
    • Prognosis
  • Establishing a Clinic
    • Overview
    • Set-up
    • Staffing & Multidisciplinary Team Approach
    • Facilities
    • Delivery Approach
    • Tailored Referrals
    • Evaluation
    • Opportunities for Training & Research
    • Barriers & Hurdles
  • Paediatrics
    • Overview
    • Management in Paediatrics
    • Assessment in Paediatrics
    • Alternative Diagnosis & Co-Morbidities in Paediatrics
    • Psychosocial Issues in Paediatrics
    • Medications in Paediatrics
    • Asthma in the Adolescent Population
  • Resources
    • Overview
    • Clinic Recommendations
    • Infographics
    • Asthma Assessment Resources
    • Systematic & Multidimensional Assessment Resources
      • Airway Components
      • Comorbidity Components
      • Risk Factor Components
    • Translation & Implementation
    • Case Studies
    • Presentations
    • Videos
    • Relevant Links
    • Key References

Preventers / Controllers

Home Medications Preventers / Controllers
asthma preventer and Controller

Asthma Preventers and Controllers

Asthma preventer or controller medications are used to control asthma and lower the risk of disease exacerbations. These are typically inhaled corticosteroids, which may be delivered with a long-acting beta-agonist (LABA) or separately. Step-wise increases in ICS dose accompanied by LABA is more likely to improve asthma control, compared to ICS alone. By definition, individuals with severe treatment refractory asthma will be on high-dose inhaled corticosteroids together with LABA.  The Australian Asthma Handbook provides information on preventer use.

Inhaled corticosteroids down regulate inflammatory gene expression, to reduce inflammation. A detailed summary of mechanisms of action and use in asthma is available in (Barnes 2010).

People with severe asthma exhibit varying degrees of corticosteroid insensitivity. Alternative approaches may be required to reduce inflammation and/or improve corticosteroid responsiveness. Maintenance low dose oral corticosteroids (OCS) may be required to minimise inflammation. However, there is limited evidence on when to start OCS, and whether long-term maintenance OCS provides benefit compared to the use of intermittent OCS only following disease exacerbation. Further, OCS use is associated with an increased risk of side-effects, including weight gain, insomnia, mental health problems, osteoporosis and cataracts. For more information see Extra-Pulmonary Comorbidities – Osteoporosis.

It is important to explain to the patient that preventers should be taken regularly, as prescribed, regardless of whether symptoms occur. Regular use is required to reduce the risk of disease exacerbation. For more information see Adherence & Inhaler technique.

Treatment Class Example Medications
Inhaled corticosteroids (ICS) Beclomethasone diproprionate

Budesonide

Ciclesonide

Fluticasone propionate

ICS / LABA Combinations Budesonide/eformoterol fumarate dihydrate

Fluticasone furoate / vilanterol trifenatate

Fluticasone propionate / eformoterol fumarate dihydrate

Flucticasone propionate / salmeterol xinafoate

LABAs (should never be used as monotherapy) Eformoterol fumarate dihydrate

Salmeterol xinafoate

The National Asthma Council Australia has developed a useful Asthma & COPD Medications chart, with images of inhaler devices and available dosages.

Previous
Next
Click here to download a printable version of the infographic below.

Access the full suite of infographics here.

oral corticosteroids asthma infographic

Last Updated on October 26, 2022

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

More results...

  • Overview
  • Relievers
  • Preventers / Controllers
  • Add-on Therapies
  • Monoclonal Antibodies
  • Bronchial Thermoplasty
For considerations relevant to the paediatric and adolescent population, please see Medications in Paediatrics

We want to know who accesses the Severe Asthma Toolkit and how it is used. Please complete our survey.

Responses will inform the continued development of the Severe Asthma Toolkit and future translation and implementation activities. Any feedback you provide will be greatly appreciated.

Complete Survey

  • Website Terms of Use
  • Website Survey
© Copyright 2018    CRICOS Provider Number 00109J    The University of Newcastle, Australia